Key Takeaways DGX's Haystack Oncology partners with Rutgers Cancer Institute on a lung cancer research trial.Quest Diagnostics offers Haystack MRD as a CLIA-validated, lab-developed test.DGX is well-placed in the expanding MRD market, driven by cancer trends and new technologies.Quest Diagnostics (DGX) company, Haystack Oncology, recently announced a research collaboration with the Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center. The partners will ...

Question-and-Answer SessionMaybe to kick it off, I was able to sit in on some of the group meetings. And I think 1 of the things you're talking a little bit about is some of the consumer initiations and applications. Maybe just talk a little bit about how you're thinking about some of these new initiatives, including the WHOOP partnership?Sam SamadExecutive VP & CFO Yes. Sure, Tycho. And first of all, thanks for having us today and hosting us. The consumer health business that we have is something that we'r ...

Quest Diagnostics (NYSE:DGX) 2025 Conference September 29, 2025 04:35 PM ET Company ParticipantsSam Samad - EVP and CFOConference Call ParticipantsTycho Peterson - Managing Director of Global Equities and Research AnalystTycho PetersonWe're going to kick it off. I'm Tycho Peterson from the life science team at Jefferies. It's my pleasure to introduce our next company, Quest Diagnostics. We're pleased to have Sam and Shawn with us today. Maybe you kick it off. I was able to sit in on some of the group meetin ...

Accessibility StatementSkip Navigation Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration Quest Diagnostics (NYSE: DGX) and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for... SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:Â DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21 ...

The Zacks Medical - Outpatient and Home Healthcare industry has been witnessing a rapid shift toward digital healthcare treatment. In the past few years, there has been a significant rise in demand for telemedicine-focused online medical and artificial intelligence (AI)-powered technology services. The rising elderly global population is necessitating many healthcare companies that were traditionally not technology-based to provide technology-enabled services to survive in the market. Per a report by Grand ...

PALO ALTO, Calif. & SECAUCUS, N.J.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shieldâ... blood- based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal c. ...

Accessibility StatementSkip Navigation With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the customer experience for health systems, hospitals, independent providers and their patients SECAUCUS, N.J., Sept. 23, 2025 /PRNewswire/ --Â Quest Diagnostics (NYSE: DGX) and Epic today announced a first-of-its-kind collaboration designed to streamline and improve experiences for healthcare providers and patients that engage Quest for laboratory testin ...

Key Takeaways Quest Diagnostics grows physician, hospital, and consumer channels through acquisitions and innovation.M&A boosts Quest Diagnostics, with LifeLabs contributing 8% of Q2 revenues.Quest Diagnostics faces rising debt and healthcare regulations that could pressure operations.Quest Diagnostics’ (DGX) solutions are focused on meeting the evolving needs of its core customers — physicians, hospitals and consumers. The company aims to generate growth through value-creating, strategically aligned acquis ...

Valued at a market cap of $20.5 billion, Quest Diagnostics Incorporated (DGX) is a clinical laboratory company that provides diagnostic testing, information, and services to physicians, hospitals, employers, and health plans. The Secaucus, New Jersey-based company operates an extensive network of laboratories, patient service centers, and mobile phlebotomy services. Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and DGX fits the label perfectly, with its market cap ...

Accessibility StatementSkip Navigation SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non- small cell lung cancer (NSCLC). Rutgers Cancer Institute t ...